Secondary objectives
dyslipidemia
DYSLIPIDEMIA

To evaluate the single-dose and multi-dose pharmacokinetics of ARO-ANG3 in HPsTo determine the reduction in fasting serum ANGPTL3 from baseline in response to a single dose and multiple doses of ARO-ANG3 as a measure of drug activity in HPs and in response to multiple doses of ARO-ANG3 in patients with dyslipidemia (all values drawn after at least 8-h fast)